Afatinib in the treatment of head and neck squamous cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 23, Issue 1, 2014, Pages 135-143

  Ferrarotto, Renata ^a   Gold, Kathryn A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Afatinib; Epidermal growth factor receptor inhibitors; Head and neck cancer

Indexed keywords

AFATINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; LAPATINIB; METHOTREXATE; PACLITAXEL; PEMETREXED; PLATINUM; RIBAVIRIN; TRASTUZUMAB;

ACNE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; COUGHING; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROTEIN EXPRESSION; QUALITY OF LIFE; RECURRENT CANCER; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84889809599     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.858696     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
2. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356(19):1944-56 (Pubitemid 46740304)
3. Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007;99(10):777-89 (Pubitemid 47073524)
4. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
5. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350-6 (Pubitemid 36025259)
6. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2(5):401-4
7. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500 (Pubitemid 38720929)
8. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82 (Pubitemid 17231334)
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78 (Pubitemid 43209104)
10. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, and oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85 (Pubitemid 41095117)
11. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27(11):1864-71
12. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343(2):342-50
13. Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009;41(10):1127-32
14. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8 (Pubitemid 37464533)
15. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91(24):2081-6 (Pubitemid 30019568)
16. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three metaanalyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355(9208):949-55 (Pubitemid 30148259)
17. Fletcher GH, Evers WT. Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck. Radiology 1970;95(1):185-8
18. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350(19):1945-52 (Pubitemid 38580197)
19. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for highrisk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937-44
20. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (9501). Head Neck 2005;27(10):843-50 (Pubitemid 41395696)
21. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171-7 (Pubitemid 46954639)
22. Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007;13(23):7086-92 (Pubitemid 350276892)
23. Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol 2013;31(11):1415-21
24. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011;29(15s):5500
25. Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebocontrolled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013;31(11):1405-14
26. Martinelli E, De Palma R, Orditura M, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158(1):1-9
27. Abdul Razak AR, Soulieres D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 2013;24(3):761-9
28. Siu LL, Hotte SJ, Laurie SA, et al. Phase II trial of the irreversible oral panhuman EGF receptor inhibitor PF-00299804 as first-line treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011;29(15s):5561
29. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
30. Canonici A, Pederson K, Browne B, et al. Effect of afatinib alone or in combination with trastuzumab in HER2-positive breast cancer cell lines. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013;31(15s):632
31. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-73 (Pubitemid 44453332)
32. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13(5):528-38
33. Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 2012;69(4):1051-61
34. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31(27):3327-34
35. Wu Y, Zhou C, Hu CP, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib versus gemcitabine/cisplatin as first-line treatment for Asian patients with EGFR mutation-positive advanced adenocarcinoma of the lung. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013;31(15s):8016
36. Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012;133(3):1057-65
37. Janjigian YY, Capanu M, Gromisch CM, et al. A phase II study of afatinib in patients with metastatic HER2-positive trastuzumab-refractory esophagogastric cancer. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013;31(15s):e15017
38. Vermorken JB, Rottey S, Ehrnrooth E, et al. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol 2013;24(5):1392-400
39. Peeters M, Machiels JP, Pilz K, et al. Phase I study of volasertib (BI 6727) combined with afatinib (BIBW 2992) in advanced solid tumros. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013;31(15s):2521
40. Chu QS, Sangha RS, Hotte SJ, et al. A phase I, dose-escalation trial of continuous and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors: final analysis. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013;31(15s):2523
41. Bouche O, Maindrault-Goebel F, Ducreux M, et al. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res 2011;31(6):2271-81
42. Cupissol D, Seiwert TY, Fayette J, et al. A randomized, open-label, phase II study of afatinib versus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: analysis of stage 2 following crossover. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013;31(15s):6001
43. Machiels JP, Licitra L, Haddad RI, et al. LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate in patients with recurrent/metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(15s):TPS5598
44. Burtness B, Bourhis J, Vermorken JB, et al. LUX head and neck 2: a randomized, double-blind, placebocontrolled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;31(15s):TPS5599
45. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28(25):3965-72
46. Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUXLung 1). J Thorac Oncol 2013;8(2):229-37
47. Tan EH, Goh C, Lim WT, et al. Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Ann Oncol 2012;23(4):1010-16
48. Gregoire V, Hamoir M, Chen C, et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebocontrolled study. Radiother Oncol 2011;100(1):62-9
49. de Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012;18(8):2336-43
50. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov [Accessed 13 July 2013]